Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

#MultipleMyeloma

Home » #MultipleMyeloma
ASH 2024 | Dr. Wenming Chen: Precision and Immune-Targeted Therapies to Overcome R/R MM Challenges

ASH 2024 | Dr. Wenming Chen: Precision and Immune-Targeted Therapies to Overcome R/R MM Challenges

Posted by By Mourabit Halima 2024.12.31
Editor's Note: The 66th Annual Meeting of the American Society of Hematology (ASH) took place in San Diego from December 7 to 10, 2024. This prestigious event brought together global…
Read More
Advancements and Disparities in Autologous Hematopoietic Stem Cell Transplantation for Lymphoma and Multiple Myeloma: Insights from China

Advancements and Disparities in Autologous Hematopoietic Stem Cell Transplantation for Lymphoma and Multiple Myeloma: Insights from China

Posted by By Mourabit Halima 2024.03.20
Introduction: Autologous hematopoietic stem cell transplantation (AHSCT) has emerged as a pivotal therapeutic modality for lymphoma and multiple myeloma (MM), offering promising outcomes in improving patient prognosis. In China, the…
Read More
Bispecific CS1-BCMA CAR-T Cells Show Promise in Treating Relapsed or Refractory Multiple Myeloma: Phase I Clinical Trial Results

Bispecific CS1-BCMA CAR-T Cells Show Promise in Treating Relapsed or Refractory Multiple Myeloma: Phase I Clinical Trial Results

Posted by By Mourabit Halima 2024.03.17
Abstract: Multiple myeloma (MM) poses significant therapeutic challenges due to its heterogeneous nature. Bispecific chimeric antigen receptor T (CAR-T) cell therapy targeting CS1 and BCMA antigens offers a novel approach.…
Read More
Enhancing Early Infection Risk Prediction in Newly Diagnosed Multiple Myeloma: A Nomogram Prognostic Model Approach

Enhancing Early Infection Risk Prediction in Newly Diagnosed Multiple Myeloma: A Nomogram Prognostic Model Approach

Posted by By Mourabit Halima 2024.03.15
Editor's note: In patients with newly diagnosed multiple myeloma (NDMM), infections pose a significant threat to morbidity and mortality, particularly within the initial months post-diagnosis. Immunoparesis, characterized by reduced levels…
Read More
Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review

Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review

Posted by By Mourabit Halima 2024.03.07
In January 2024, a study led by Professor Ting Niu from West China Hospital, Sichuan University was published in the international academic journal ——Frontiers In Oncology. The title of the…
Read More
Enhancing Early Infection Risk Prediction in Newly Diagnosed Multiple Myeloma: A Nomogram Prognostic Model Approach

Enhancing Early Infection Risk Prediction in Newly Diagnosed Multiple Myeloma: A Nomogram Prognostic Model Approach

Posted by By Mourabit Halima 2024.02.28
Editor's note: In patients with newly diagnosed multiple myeloma (NDMM), infections pose a significant threat to morbidity and mortality, particularly within the initial months post-diagnosis. Immunoparesis, characterized by reduced levels…
Read More
Recent Posts
  • ISEH 2025 | Professor Tao Cheng: Revitalizing Sino-Japanese Hematology Exchange and Exploring the Frontiers of Cell and Gene Therapy
  • CSCO 2025 │ Professor Lili Mao: Updates to Perioperative Therapy in the 2025 CSCO Melanoma Guidelines
  • Professor Haibo Wang: Advancing Comprehensive Breast Cancer Care through Innovation and Multidisciplinary Collaboration
  • “Those Who Fail to See the Whole Cannot Govern the Parts” — Professor Qiang Liu Shares New Perspectives on Neoadjuvant Therapy for Breast Cancer
  • CSCO Journey │ Professor Man Li: CSCO Member No. 168, Witness to China’s Leap Forward in Clinical Oncology
Recent Comments
    Archives
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2025 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Media Medic Publishing Company Limited(HK)
    赛美出版有限公司(香港)
    Scroll to Top